Daily administration of atorvastatin and simvastatin for one week improves cardiac function in type 1 diabetic rats

Maria J Crespo1, Nildris Cruz, Jose Quidgley

  • 1Department of Physiology, University of Puerto Rico School of Medicine, San Juan, P.R., USA.

Pharmacology
|February 22, 2014
PubMed

Insights

Short-term statin therapy, specifically atorvastatin (AV) and simvastatin (SV), significantly improved cardiac function in diabetic rats. Pravastatin (PV) showed no benefits, highlighting AV and SV as potential perioperative treatments for diabetic patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Diabetology

Background:

  • Perioperative statin administration may improve cardiovascular outcomes in surgery patients.
  • Optimal statin choice, timing, and effectiveness in diabetic patients with compromised cardiac function remain unclear.

Purpose of the Study:

  • To compare the effects of simvastatin (SV), pravastatin (PV), and atorvastatin (AV) on cardiovascular status in anesthetized diabetic rats.
  • To evaluate short-term statin administration for improving cardiac performance under hyperglycemic conditions.

Main Methods:

  • Streptozotocin-induced diabetic rats with compromised cardiac function were used.
  • Rats received daily doses of 10 mg/kg/day of SV, PV, or AV.
  • Cardiac status was assessed via echocardiography at 24 hours and after 1 week of treatment.

Main Results:

  • One-week daily administration of AV and SV significantly improved ejection fraction and cardiac output index in diabetic rats.
  • AV also significantly increased stroke volume, while PV showed no beneficial effects.
  • No improvements in cardiovascular parameters were observed after only 24 hours of statin administration.

Conclusions:

  • Daily administration of atorvastatin and simvastatin for one week enhances cardiac performance in anesthetized diabetic rats.
  • These findings suggest potential clinical implications for short-term statin use in improving perioperative outcomes for diabetic patients.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
75
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
28
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
32
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K